Karl Hård
Investor Relations Contact en EGETIS THERAPEUTICS AB .
Perfil
Karl J.
Hård is currently the VP, Head-Investor Relations & Communications at Egetis Therapeutics AB.
Previously, he worked as an Investor Relations Contact at AstraZeneca PLC and as an Assistant Professor at the University of Leiden.
He also served as the Head-Investor Relations & Corporate Communications at Redx Pharma Plc from 2016 to 2017 and as the Head-Investor Relations & Communications at Kiadis Pharma NV from 2017 to 2018.
Dr. Hård holds a doctorate degree from the University of Utrecht and a graduate degree from the University of Helsinki.
Cargos activos de Karl Hård
| Empresas | Cargo | Inicio |
|---|---|---|
| EGETIS THERAPEUTICS AB | Investor Relations Contact | 01/02/2022 |
Antiguos cargos conocidos de Karl Hård.
| Empresas | Cargo | Fin |
|---|---|---|
| KIADIS PHARMA N.V. | Investor Relations Contact | 31/12/2018 |
| REDX PHARMA PLC | Investor Relations Contact | 02/07/2017 |
| University of Leiden | Corporate Officer/Principal | - |
| ASTRAZENECA PLC | Public Communications Contact | - |
Formación de Karl Hård.
| University of Utrecht | Doctorate Degree |
| University of Helsinki | Graduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Empresas privadas | 1 |
|---|---|
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Karl Hård
